Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Pennsylvania for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Pennsylvania only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Pennsylvania (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Dennis Jerdan (NPI 1588652200)

Field	Value
Entity Type	Individual
Organization	Dennis Jerdan
Address	2360 Maryland Rd
City	Willow Grove
State	PA
ZIP	19090
Taxonomy	Rheumatology Physician
NPI Enumerated	October 6, 2005

Payer Source	Total Paid
Medicare	$2.5M
Medicaid	$0

Key Findings

This provider’s Medicare footprint is the primary revenue source: lifetime Medicare revenue is $2.5M while there is no Medicaid billing on file, so the practice is effectively single‑payer (Medicare) in the claims data available. This concentration in one payer suggests limited state Medicaid exposure and little diversification of public-payer revenue.

Revenue is highly concentrated in a small set of biologic injectable products: the precomputed top 3 Medicare codes by revenue account for 44.5% of this provider's total Medicare revenue, led by J3262 ($394.4K, 15.7%), J0897 ($386.6K, 15.4%), and J0129 ($338.3K, 13.5%). These three drug codes alone drive nearly half of Medicare revenue, indicating dependence on high‑cost biologic and specialty drug administration.

The CPT/HCPCS mix is consistent with a rheumatology practice that also operates an infusion/administration suite: high‑revenue items are injectable biologics (J3262, J0897, J0129, J1602, J1745) and the provider also reports chemotherapy/infusion administration codes such as 96413 ($60.5K) and 96401 ($50.8K). The presence of both drug and infusion administration codes implies in‑office or facility‑based dispensing and supervised parenteral therapy rather than only office consultations or self‑administered therapies.

J0897 (denosumab) is a clear competitive outlier: it generates $386.6K (15.4% of Medicare revenue) and the provider ranks #245 of 10057 providers nationally (98th percentile; notably above typical national volume for this code). That rank indicates this provider is a major national participant for denosumab administration compared with peers.

Office visit and infusion throughput are also above typical peer levels: 99214 accounts for $96K (990 claims) and ranks #11713 of 479517 providers nationally (98th percentile; notably above typical national volume for this code), while 96401 ranks #115 of 3868 providers nationally (97th percentile; notably above typical national volume for this code). Those high percentiles for both E/M and infusion administration suggest steady ambulatory volume and frequent supervised injectable/infusion encounters.

Several other biologic and specialty drug codes show elevated but more typical volumes: J3262 ($394.4K) ranks #99 of 618 (84th percentile; typical, unremarkable volume for this code) and J1602 ($299K) ranks #160 of 1041 (85th percentile; typical, unremarkable volume for this code), indicating the practice treats a broad mix of biologics without being the dominant national provider across all drug categories. The code mix therefore reflects breadth in biologic therapy provision rather than monopoly in a single drug class.

Although immunoglobulin therapy appears in the top codes (J1459, $172.1K), its national rank (#20 of 44 providers; 56th percentile; typical, unremarkable volume for this code) suggests modest participation among a small specialty cohort for that product. This pattern points to occasional use of IVIG alongside more frequent biologic injections and infusions.

The provider has an established NPI (enumerated 2005-10-06, ~21 years ago), indicating long tenure in the Medicare program; combined with the billing pattern of sustained biologic and infusion activity, this suggests an operationally stable practice with ongoing infusion capacity. Given the lack of Medicaid billing, payers should view this entity as a Medicare‑focused supplier of in‑office biologics and infusion services with potential sensitivity to drug reimbursement and specialty‑drug contract terms.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

25 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J3262	Injection, tocilizumab, 1 mg	78,880	$10	$394.4K
J0897	Injection, denosumab, 1 mg	21,480	$20	$386.6K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	9,950	$30	$338.3K
J1602	Injection, golimumab, 1 mg, for intravenous use	29,900	$10	$299K
J3111	Injection, romosozumab-aqqg, 1 mg	29,400	$10	$235.2K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	6,740	$30	$175.2K
J1459	Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg	4,650	$40	$172.1K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	35,600	$1	$142.4K
J9312	Injection, rituximab, 10 mg	1,740	$60	$109.7K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	990	$100	$96K

Showing 1–10 of 25

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 25 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Pennsylvania Distribution

Dennis Jerdan — 4 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Pennsylvania

Full comparison — all codes billed, vs. state median

25 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	22	60	7,900	$30	$353.8K
J3262	7	30	45,000	$1	$268K
J0717	36	70	38,610	$1	$223.7K
J9312	11	10	2,330	$60	$192K
J1602	9	60	11,780	$10	$181.6K
J3111	12	60	16,590	$10	$176.8K
J1745	14	80	3,630	$30	$115.4K
J1459	2	10	3,070	$40	$114.2K
J0897	13	530	2,460	$20	$89.6K
96413	14	300	140	$100	$19.8K

Showing 1–10 of 25

Related Providers

Other providers that share a Tax Identification Number (TIN) with Dennis Jerdan, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Sarah Coleman	PA	Rheumatology Physician	$2.4M	$0
Elana Eisner	PA	Rheumatology Physician	$2.1M	$0
Charles Pritchard	PA	Rheumatology Physician	$2.1M	$0
David Chesner	PA	Rheumatology Physician	$1.6M	$0
Marguerite Mcgarvey	PA	Rheumatology Physician	$1.5M	$0
Dana Jacobs-kosmin	PA	Rheumatology Physician	$1.4M	$0
Monica Mohile	PA	Rheumatology Physician	$1.4M	$0
Thomas Quinn	PA	Rheumatology Physician	$883.9K	$0
Stephanie Morris	PA	Rheumatology Physician	$742.6K	$0
Anjali Bal	PA	Internal Medicine Physician	$731.1K	$0

Nearby Providers

Other providers in the same ZIP code as Dennis Jerdan, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Bayada Home Health Care, Inc.	PA	Home Health Agency	$0	$16M
Central Behavioral Health	PA	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$8.6M
Second Alarmer's Assn & Rescue Squad Of Montgomery County Inc	PA	Paramedic	$1.2M	$1.8M
Montgomery County Advanced Medical Imaging, LLC	PA	Clinic/Center	$1M	$0
Sally Pullman-mooar	PA	Rheumatology Physician	$752.4K	$0
Abington Surgical Center	PA	Ambulatory Surgical Clinic/Center	$653.8K	$0
Kevin Lu	PA	Internal Medicine Physician	$626K	$0
Chad Krueger	PA	Orthopaedic Surgery Physician	$358.1K	$0
Joshua Goldberg	PA	Otolaryngology Physician	$232.1K	$2.3K
Victor Ghantous	PA	Nephrology Physician	$205.9K	$0

Dennis Jerdan — Billing Profile & Reimbursement Data

Sign up for Dennis Jerdan — Billing Profile & Reimbursement Data policy alerts

Dennis Jerdan — Billing Profile & Reimbursement Data

Sign up for Dennis Jerdan — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References